Marija Menih1, Miljenko Križmarić2,3, Tanja Hojs Fabjan4. 1. Department of Neurology, University Medical Centre Maribor, Ljubljanska 5, 2000, Maribor, Slovenia. marija.menih@gmail.com. 2. Faculty of Medicine, University of Maribor, Taborska 8, 2000, Maribor, Slovenia. 3. Faculty of Health Sciences, University of Maribor, Žitna 15, 2000, Maribor, Slovenia. 4. Department of Neurology, University Medical Centre Maribor, Ljubljanska 5, 2000, Maribor, Slovenia.
Abstract
BACKGROUND: An elevated level of von Willebrand factor (VWF) is associated with an increased risk for coronary heart disease and ischemic stroke. The objective of the study was to determine whether the level of VWF is associated with the cardioembolic subtype of ischemic stroke, stroke severity, and clinical outcome. PATIENTS AND METHODS: In this study 108 patients suffering from acute ischemic stroke (AIS) were included. According to the etiology of the stroke, patients were classified into the subtype of cardioembolic (CE) stroke and the group with non-CE stroke. Patients with non-CE stroke were further classified into subtype of large vessel disease, subtype of small vessel disease and subtype of cryptogenic stroke. Laboratory tests were performed in the acute phase and VWF was determined for all patients. The National Institutes of Health Stroke Scale (NIHSS) was applied on admission and the modified Rankin scale (MRS) at discharge. RESULTS: The only significant factor which predicted CE stroke was age (B = 0.077; standard error, SE = 0.026; P = 0.003). The level of VWF was not significantly higher in the group with the cardioembolic stroke compared to the group with non-CE stroke. Patients assessed by NIHSS on admission as the most disabled had significantly higher levels of VWF (B = 0.006; SE = 0.003; P = 0.045). Those with higher scores of MRS at discharge also had significantly increased levels of VWF (B = 0.006; SE = 0.003; P = 0.028). CONCLUSION: Among the patients with ischemic stroke, levels of VWF were not increased in those with CE stroke. High levels of VWF were associated with greater severity of stroke as well as with poor clinical outcome.
BACKGROUND: An elevated level of von Willebrand factor (VWF) is associated with an increased risk for coronary heart disease and ischemic stroke. The objective of the study was to determine whether the level of VWF is associated with the cardioembolic subtype of ischemic stroke, stroke severity, and clinical outcome. PATIENTS AND METHODS: In this study 108 patients suffering from acute ischemic stroke (AIS) were included. According to the etiology of the stroke, patients were classified into the subtype of cardioembolic (CE) stroke and the group with non-CE stroke. Patients with non-CE stroke were further classified into subtype of large vessel disease, subtype of small vessel disease and subtype of cryptogenic stroke. Laboratory tests were performed in the acute phase and VWF was determined for all patients. The National Institutes of Health Stroke Scale (NIHSS) was applied on admission and the modified Rankin scale (MRS) at discharge. RESULTS: The only significant factor which predicted CE stroke was age (B = 0.077; standard error, SE = 0.026; P = 0.003). The level of VWF was not significantly higher in the group with the cardioembolic stroke compared to the group with non-CE stroke. Patients assessed by NIHSS on admission as the most disabled had significantly higher levels of VWF (B = 0.006; SE = 0.003; P = 0.045). Those with higher scores of MRS at discharge also had significantly increased levels of VWF (B = 0.006; SE = 0.003; P = 0.028). CONCLUSION: Among the patients with ischemic stroke, levels of VWF were not increased in those with CE stroke. High levels of VWF were associated with greater severity of stroke as well as with poor clinical outcome.
Entities:
Keywords:
Clinical outcome; Ischemic stroke; Severity of stroke; TOAST classification; von Willebrand factor
Authors: Michelle A H Sonneveld; Anouk C van Dijk; Evita G van den Herik; Janine E van Loon; Lonneke M L de Lau; Aad van der Lugt; Peter J Koudstaal; Moniek P M de Maat; Frank W G Leebeek Journal: Atherosclerosis Date: 2013-08-02 Impact factor: 5.162
Authors: W Zareba; G Pancio; A J Moss; V G Kalaria; V J Marder; H J Weiss; L F Watelet; C E Sparks Journal: Thromb Haemost Date: 2001-09 Impact factor: 5.249
Authors: Dirk C Felmeden; Charles G C Spencer; Natali A Y Chung; Funmi M Belgore; Andrew D Blann; D Gareth Beevers; Gregory Y H Lip Journal: Am J Cardiol Date: 2003-08-15 Impact factor: 2.778
Authors: Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma Journal: Thromb Haemost Date: 2018-05-30 Impact factor: 5.249
Authors: Noémi Klára Tóth; Edina Gabriella Székely; Katalin Réka Czuriga-Kovács; Ferenc Sarkady; Orsolya Nagy; Levente István Lánczi; Ervin Berényi; Klára Fekete; István Fekete; László Csiba; Zsuzsa Bagoly Journal: Front Neurol Date: 2018-01-23 Impact factor: 4.003
Authors: Samantha J Donkel; Boutaina Benaddi; Diederik W J Dippel; Hugo Ten Cate; Moniek P M de Maat Journal: Arterioscler Thromb Vasc Biol Date: 2019-03 Impact factor: 8.311